News & Updates

A scientific statement endorsed by the American Heart Association (AHA) has urged cardiothoracic surgeons to get more involved in the care of patients at high risk for pulmonary embolism (PE) – and to do it much earlier – to improve outcomes.

Being fat contributes to the development of cardiopulmonary (CP) multimorbidity (MM), reports a study. As a result, adiposity may be targeted by future interventions to help prevent MM.

Oligoprogression is defined as limited metastatic areas that progress while on/off systemic therapy in the context of oligometastatic or polymetastatic disease. Individuals with non-small cell lung cancer (NSCLC) metastasis with oligoprogression may benefit from local ablative radiotherapy, also known as stereotactic body radiation therapy (SBRT), stereotactic ablative radiotherapy (SABR), or stereotactic radiosurgery (SRS).

A single dose of ceftriaxone appears to reduce the risk of developing early ventilator-associated pneumonia (VAP) in patients with acute brain injury, according to the PROPHY-VAP study.

In the treatment of chronic rhinosinusitis (CRS), exhalation delivery system with fluticasone (EDS-FLU) provides relief from symptoms while reducing intrasinus disease and the incidence of acute exacerbations, regardless of the presence of polyps, as shown in the phase III trials ReOpen1 and ReOpen2.

In patients with idiopathic pulmonary fibrosis-related cough, treatment with low-dose controlled-release morphine leads to reduced daytime cough frequency and better quality of life, according to data from the phase II PACIFY COUGH crossover trial.

SARS-CoV-2 vaccination appears to confer protection against long COVID in the paediatric population, with the protective benefit being stronger in teens.

Testing for eosinophils during chronic obstructive pulmonary disease (COPD) flare-ups to guide prednisolone treatment compares favourably with standard of care, with no increase in treatment failures, symptoms, or lung function decline, according to data from the phase III STARR2 trial.